Genetic polymorphisms in CYP3A4 and CYP3A5 have been studied in 189 CML patients and no association was found with TKI therapy outcomes at 12 months after starting therapy [14]. The gene discussed is CYP3A5; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.